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There is extensive, clinical use of antiinflam-
matory drugs that inhibit prostaglandin synthesis in
most, if not all, organs in the body. Much of the
therapeutic efficacy of these agents depends on a
reduction of prostaglandin synthesis at the site of
inflammation. Not surprisingly, many of the side-
effects of these drugs are secondary to decreased
prostaglandin synthesis in brain, vasculature, stom-
ach, lung, and kidney. In this review, we will focus
attention on the effects of these antiinflammatory
compounds on renal function, with particular em-
phasis on renin secretion, control of renal blood
flow (RBF), and glomerular filtration rate (GFR).
To describe these renal consequences of prosta-
glandin inhibition, we will briefly review the bio-
chemistry of prostaglandin synthesis and the major
known physiologic actions of prostaglandins in the
kidney.
Renal synthesis ofprostaglandins and thromboxane
Prostaglandins, endoperoxides, and thrombox-
anes are synthesized in the kidney. Arachidonic
acid, a 20 carbon fatty acid, is the substrate for the
synthesis of these products. The synthetic enzymes
are collectively referred to as prostaglandin (PG)
synthetase, which includes fatty acid cyclo-oxygen-
ase (forming endoperoxides), endoperoxide isomer-
ase (forming PGE2), endoperoxide reductase (form-
ing PGF2), prostacyclin synthetase (forming PGI2),
and thomboxane synthetase (forming TxA2) [1]. 6-
keto-PGF1, and TxB2 are the spontaneous decom-
position products of prostacyclin and TxA2, respec-
tively. Prostacyclin and TxA2 are unstable in aque-
ous solutions at a pH of 7.4, and therefore 6-keto-
PGF1a and TxB2 are used as stable markers of their
labile precursors. Figure 1 summarizes these syn-
thetic pathways.
These prostaglandins and thromboxanes are
formed in both the renal medulla and cortex, al-
though the activity of prostaglandin synthetase is
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fivefold to tenfold greater in the medulla [2]. There
are differences between species as to the relative
abundance of each end product of arachidonic acid
oxygenation. It should be stressed that the majority
of studies have used slices or microsomal extracts
of renal cortex and medulla and, therefore, do not
define or localize the segments of the nephron in
which the prostaglandins are formed. Microsomes
obtained from the medulla and cortex of human kid-
neys synthesize PGI2, PGF2a, PGE2, TxA2, and
PGD2 [3]. In these in vitro experiments, PGI2,
PGE2, and PGF20 were the most abundant products;
the synthesis of TxA2 was, however, unequivocal
[3]. Most prior publications have identified TxA2
only after ureteral obstruction and not in the normal
kidney [4]. In most species, PGE2, PGI2, and PGD2
are vasodilatory, whereas endoperoxides and TxA2
are vasoconstrictor [5]. PGFZ,. is a weak vasocon-
strictor. The in vivo measurement of renal prosta-
glandin synthesis has depended on the assay of re-
nal venous plasma and urine. The prostaglandins in
renal venous plasma and in urine are formed in the
kidney and undoubtedly are not delivered to the
kidney in the arterial blood [5, 6].
Stimulation of renal prostaglandin synthesis with
bradykinin or angiotensin II (All) increases PGE2
and PGF2 in both renal venous plasma and in urine
[6-8]. Inhibition of renal prostaglandin synthesis
with indomethacin or meclofenamate reduces renal
venous and urinary concentrations of PGE2 and
PGF2a by 50 to 75% [9]. Renal excretory rates of
prostaglandins offer several advantages over renal
venous plasma in the assessment of renal synthetic
rates [5]. Urine collections provide an integrated
measure of prostaglandin synthesis over hours to
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days, urine can be conveniently obtained non-
invasively, and urinary prostaglandin concentra-
tions are less likely to be increased artifactually by
nonrenal cells, whereas plasma concentrations may
be elevated by platelet and leukocyte production of
prostaglandins.
Recent work has emphasized the specific sites of
prostaglandin synthesis in the kidney. Table 1 sum-
marizes the incomplete information available from
these studies. Several precautions should be ex-
pressed about this summary. The relative abun-
dance of end products can be altered, in vitro, by
cofactors and by the concentration of arachidonic
acid. For example, the amount of PGE2 formed by
renal microsomes is dramatically increased by re-
duced glutathione [1]. The various studies summa-
rized in Table I used different assays (radiometric
thin-layer chromatography and radioimmunoas-
say), and the array of measured prostaglandins is
obviously a function of assay sensitivity. Nonethe-
less, several conclusions seem warranted. First,
cortical structures such as glomeruli and arterioles
synthesize prostaglandins that are capable of con-
trolling cortical physiologic events, including renal
vascular resistance, renin secretion, and GFR. Old-
er theories postulating that renal prostaglandins
were primarily synthesized in the medulla and sub-
sequently delivered to the cortex (via the return of
urine to cortical tubules?) are unnecessary [17, 18].
It is simpler to assume that cortical functions are
modulated by cortical synthesis of prostaglandins
and that medullary events (medullary blood flow,
collecting tubule response to vasopressin, sodium
and chloride reabsorption in the Loop of Henle) are
moderated by medullary synthesis of prostaglan-
dins. Second, the prevalence of specific prostaglan-
dins varies between different segments of the neph-
ron. The physiologic significance of this observa-
tion is presently unknown.
The major known stimuli of renal prostaglandin
synthesis are listed in Table 2. These data were ob-
Table!. Renal sites of prostaglandin synthesis
Tissue Productsa S
Glomeruli [10, 11] PGF2, > PGE2, > TxA2, > PG12 > PGDZ
Arterioles [12] PGI2
Cortical tubules
[10, 11] Trace amounts of PGE2 and PGF2
Collecting tubules
(papillary) [13, 14] PGE2, > PGI2, > PGF2> PGD2
Medullary interstitial
cells [15, 16] PGE2 >> PGFZ
The relative abundance of each end product is affected in vi-
tro by cofactors and the concentration of arachidonic acid. The
prevalence of these prostaglandins, in vivo, is speculative.
h TxA2 and PGI2 synthesis were measured indirectly by the
amounts of TxB2 and 6-keto-PGF1,.
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Fig. 1. Biosynthesis of prostaglandins and thromboxane. All of the products shown in this figure have been found in kidney or urine.
Refer to the text for details.
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Table 2. Stimuli of prostaglandin and thromboxane
synthesis in the kidney
Peptides Angiotensin II [6, 7]
Bradykinin [6, 8]
Vasopressin [19—21]
Disease Ischemia (renal arterial stenosis or hypo-
tension) [6, 22]
Ureteral obstruction (unilateral) [4, 23]
Cirrhosis with ascites [24]
Acute renal failure? [25]
Hypertension? [26]
Miscellaneous Catecholamines [27, 28]
Calcium ionophore (A23 187) [29]
Furosemide [30]
tamed in vivo with animals and man, in vitro with
renal slices, and in vitro with cell cultures of renal
medullary interstitial cells. The best documented
mechanism, through which prostaglandin synthesis
is stimulated, is increased availability of arachidon-
ic acid [19]. These stimuli enhance the activity of
phospholipase A2 and thereby deacylate phospho-
lipids to yield more arachidonic acid. The increased
concentration of arachidonic acid, in the presence
of an active cyclo-oxygenase, rapidly forms more
prostaglandins and thromboxane, which can appear
within seconds to minutes. It is probable, although
unproved, that diseases such as unilateral ureteral
obstruction and renal ischemia stimulate the syn-
thesis of prostaglandins and/or thromboxane
through the intrarenal release of All, bradykinin, or
catecholamines. Indirect evidence suggests that
blockade of All and of alpha adrenergic receptors
will substantially reduce the compensatory release
of renal prostaglandins in response to decreased
renal perfusion [31]. Several different experiments
also suggest that ureteral obstruction and chronic
vasopressin administration can stimulate increased
enzyme synthesis of either phospholipase, cyclo-
oxygenase, or thromboxane synthetase [32, 33]. It
Table 3. Inhibitors of fatty acid cyclo-oxygenase
Aspirin type Acetylsalicyclic acid
Salicyclic acida
Phenacetina
Nonsteroidal antiinflam-
matory drugs Indomethacin (Indocin®)
Meclofenamate
Phenylbutazone (Butazolidin®)
Ibuprofen (Motrin®)
Naproxen (Naprosyn®)
Tolmetin (Tolectin®)
Fenoprofen (Nalfon®)
Sulindac (Clinoril®)
a Salicyclic acid must be converted, in vivo, to gentisic acid;
phenacetin is converted to acetaminophen. These metabolites
are active inhibitors of prostaglandin synthesis [35].
seems likely that increased synthesis of enzymes
beyond the phospholipase step may play an impor-
tant role in the more chronic responses of the pros-
taglandin and thromboxane pathways.
Inhibitors of prostaglandin synthesis. Since the
original observation by Vane [34] and Flower and
Vane [35] that aspirin inhibited prostaglandin syn-
thesis, a large number of compounds have been dis-
covered that inhibit the fatty acid cyclo-oxygenase.
Table 3 enumerates many of the compounds com-
mercially available and used in clinical medicine.
Many other congeners are available for laboratory
use. The efficacy of these drugs, as inhibitors of
prostaglandin synthesis, varies between different
organs (that is, different sources of microsomal cy-
clo-oxygenase studied in vitro) [35]. There are also
in vivo differences by virtue of metabolism and ex-
cretion of the drug and perhaps because of limited
access to the intracellular cyclo-oxygenase enzyme.
Acetylsalicyclic acid acetylates the cyclo-oxygen-
ase protein and thereby irreversibly inhibits this en-
zyme [36]. The effect of aspirin is dissipated only
after the synthesis of new enzyme. Unlike the plate-
let cyclo-oxygenase, which is inhibited by aspirin
for the life of the cell, renal cyclo-oxygenase turn-
over or synthetic rates are rapid, and the aspirin-
mediated inhibition disappears after 24 to 48 hours
[37]. The "nonaspirin," nonsteroidal, antiinflam-
matory drugs inhibit reversibly the cyclo-oxygen-
ase. These drugs apparently dissociate from the cy-
clo-oxygenase protein, and consequently, their in-
hibitory effects are progressively attenuated over 8
to 24 hours. After in vivo administration, these
agents rarely inhibit prostaglandin synthesis by
more than 80% [9]. It is unknown whether the resid-
ual, uninhibited 20% of prostaglandin secretion by
the kidney is sufficient to support prostaglandin-de-
pendent processes. Many investigators, possibly er-
roneously, have concluded that indomethacin and
related compounds inhibit all prostaglandin produc-
tion and therefore any physiologic function remain-
ing after indomethacin is independent of prostaglan-
dins. There may be pitfalls in this type of reasoning.
An additional shortcoming of some studies, espe-
cially those using chronic therapy with indometha-
cm and its analogues, is the failure to document the
extent of fatty acid cyclo-oxygenase inhibition. We
have recently reported that the inhibition of renal
excretion of PGE2 and PGF2, after chronic ad minis-
tration of indomethacin to diabetes insipidus rats,
was progressively and completely overcome by
coadministration of the vasopressin analogue, 1-
desamino-d-arginine vasopressin (dDAVP) [33].
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Stated differently, renal excretion of PGE2 and
PGF2 increased tenfold and returned to normal val-
ues in indomethacin-treated rats with diabetes in-
sipidus who recived 12 to 16 days therapy with
dDAVP [33]. Any experimental protocol, whether
in animals or man, using nonsteroidal inhibitors of
prostaglandin synthesis should document the extent
of inhibition by measurement of one or more of the
prostaglandin or thromboxane end products.
These nonsteroidal agents are not selective inhib-
itors of fatty acid cyclo-oxygenase [5]. Indometha-
cm, the best studied prototype, has many other ac-
tions, some of which have no direct bearing on
prostaglandin metabolism. Table 4 lists these ef-
fects. Because of these multiple actions, especially
at high doses of indomethacin, one must be cautious
in the interpretation that any physiologic function is
prostaglandin-mediated if it is attenuated after indo-
methacin. The dependence of any process on pros-
taglandin synthesis should be examined with sever-
al prostaglandin inhibitors, evaluated after infusions
of arachidonic acid, and examined after replace-
ment of specific prostaglandins in the presence of
cyclo-oxygenase blockade. With this approach, the
nonspecific (and "nonprostaglandin") actions of in-
domethacin will be recognized, and misinterpreta-
tion will be minimized.
Prostaglandins, RBF, GFR, and drug-induced renal
failure
Animal studies. Renal prostaglandins exert little
or no important control over resting or basal RBF in
conscious animals. These conclusions are based on
the inability of indomethacin or meclofenamate to
reduce RBF despite significant reductions of prosta-
glandin synthesis [9, 48, 49]. We found that inhibi-
tion of renal prostaglandin synthesis did not alter
RBF or renal vascular resistance in unanesthetized
dogs. These results contrast with earlier work dem-
onstrating that inhibition of prostaglandin synthesis
with indomethacin, meclofenamate, ibuprofen, and
tolmetin reduces RBF in anesthetized and in-
strumented animals and in isolated perfused kid-
neys [50-54]. The role of renal prostaglandins in the
control of resting RBF in man remains an open
question. Nowak and Wennmalm have reported
that 50 mg of indomethacin, given i.v., acutely in-
creased renal vascular as well as splanchnic resis-
tance (30% and 16%) [55]. Infusion of PGE1, 4 to 8
mg/mm, returned renal vascular resistance and
RBF to normal. Whether these increments of renal
vascular resistance, after indomethacin, are directly
related to prostaglandin inhibition remains unclear,
Table 4. Actions of indomethacin
A. Prostaglandin-related actions
1. Inhibit prostaglandin synthesis (cyclo-oxygenase) [35]
2. Reduce prostaglandin degradation (15-hydroxy-
dehydrogenase) [38]
3. Reduce conversion of PGE2 to PGFZ, (9-ketoreductase)
[39]
4. Reduce arachidonic acid release (phospholipase A2) [40]
5. Inhibit renal tubular transport of prostaglandins [41]
B. Prostaglandin-unrelated actions
1. Inhibit cyclic AMP degradation (phosphodiesterase) [42]
2. Decrease cellular efflux of cyclic AMP [43]
3. Inhibit cyclic AMP-stimulated protein kinase [44]
4. Compete with aldosterone for mineralocorticoid receptors
[45]
5. Reduce angiotensin II binding to adrenal cells [46]
6. Alter smooth muscle contractility by inhibition of calcium
transport [47]
because nonvisceral resistance did not rise after in-
domethacin and yet PGE1 infusion also increased
nonvisceral blood flow. The changes of RBF in re-
sponse to both indomethacin and PGE1 were ob-
served acutely, over 1 hour. It seems clear that re-
nal ischemia or renal vasoconstriction will stimulate
renal prostaglandin synthesis. This release of PGE2
(?PGI2 also) is compensatory and homeostatically
modulates the extent of vasoconstriction. Figure 2
shows that the effects of All or of renal arterial con-
striction on RBF in the dog kidney are inversely re-
lated to the compensatory response of the PGE2 se-
cretory rate as measured by renal venous concen-
trations of PGE2. In these dogs, the compensatory
return of RBF towards control levels, after the on-
set of renal arterial constriction or renal arterial in-
fusion of All, was positively correlated with the in-
crement of renal venous PGE2. More severe is-
chemia, induced by complete occlusion of the renal
artery for 1 to 3 mm, leads to postocciusive hyper-
emia with a predominant increase of RBF to the in-
ner cortex. Indomethacin significantly reduces this
reactive hyperemia in the dog [55a] and the cat [56]
but not in the rabbit 157]. In contrast, prostaglan-
dins may not be important in the autoregiilatory
control of GFR and RBF to alterations of perfusion
pressure between 75 and 150 mm Hg because indo-
methacin and meclofenamate do not interfere with
autoregulation in the dog [52, 58] or the rat 159]. It is
important to also note several studies showing that
sodium depletion, in the dog, sensitizes the animal
to deleterious renal effects of prostaglandin inhibi-
tion; that is, decreased GFR, RBF, and sodium ex-
cretion [60, 61]. If renal synthesis of vasodilatory
prostaglandins is blocked by indomethacin or mec-
lofenamate, then vasoconstrictor effects of intra-
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renal All or norepinephrine, and renal neural stimu-
lation are enhanced in dogs and cats [59, 62-65].
Hemorrhagic hypotension in dogs and baboons,
when combined with cyclo-oxygenase blockade by
indomethacin, meclofenamate, or R020-5720, in-
duces more severe decrements of GFR and RBF
than were observed in untreated, hemorrhaged ani-
mals [66, 67]. These observations in vasocon-
stricted animals are very important in our inter-
pretations of the deleterious effects of indomethacin
on GFR and RBF in vasoconstricted patients.
Baylis et al have demonstrated effects of PGE on
the glomerular microcirculation. Infusions of PGEI
into the rat renal artery reduced the glomerular ul-
trafiltration coefficient and increased glomerular
plasma flow. The net effect was no change in the
single nephron GFR [68]. It is well established that
infusions of PGE2 and PGI2 do not alter the whole
kidney GFR in normal animals. The response of the
glomerulus to All is also affected by the synthesis
of prostaglandins [69]. Rats treated with cyclo-oxy-
genase inhibitors, prior to the infusion of All,
showed greater decrements of single nephron GFR
and plasma flow and greater increments of afferent
or efferent arteriolar resistance [69]. Inhibition of
prostaglandin synthesis in rats with chronic (4
week) unilateral partial occlusion of the ureter in-
creased arteriolar resistance and decreased gb-
merular plasma flow and GFR [70]. These studies
clearly indicate a significant "protective" role for
renal prostaglandins (vasodilatory) to preserve nor-
mal gbomerular dynamics in the face of vasocon-
strictor influences.
Because sustained, severe cortical vasoconstric-
tion is observed in most, if not all, forms of both
experimental and human acute renal failure, some
studies have attempted to potentiate or exacerbate
the development of renal failure by prior adminis-
tration of indomethacin. Experiments in rats, using
glycerol or mercuric chloride, showed no potentia-
tion or renal injury after prior inhibition of prosta-
glandin synthesis [71]. Similar results were obtained
in rabbits given mercuric chloride [72]. Rabbits giv-
en glycerol and huge doses of indomethacin (24 mgI
kg over 6.5 hours) developed a more severe renal
failure [72]. These experiments in animals do not
establish any clear relationship between inhibition
of prostaglandin synthesis and an increased risk of
acute renal failure.
Because of our belief that intrarenal prostaglan-
dins serve a protective role under conditions of inef-
fective circulating volume and high levels of All,
we designed experiments in dogs in which hepatic
disease was induced by chronic bile duct ligation
and renal function was then measured 36 to 78 days
later, before and after an acute dose of indometha-
cm. RBF and GFR decreased and renal vascular re-
sistance increased in all bile duct-ligated dogs after
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Fig. 2. Relation between PGE2 secretion and RBF. The renal artery was partially constricted for 12 mm or angiotensin II was infused,
intrarenally, at 50 ng/min for 15 mm. The values for RBF are shown as decrements or increments. These changes actually depict the
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the inhibition of renal prostaglandin synthesis.
Changes in RBF and GFR were greater in dogs with
ascites. There were no significant changes of RBF
in the sham-operated controls. Indomethacin pro-
duced a 90 to 95% reduction in the renal excretion
of both PGE2 and PGF2,. in both the sham-operated
controls and the bile-duct-ligated experimental
animals. The accompanying changes in plasma
renin activity, and fractional sodium excretion were
variable and did not achieve statistical significance.
Nevertheless, the hypothesis warrants further ex-
ploration that hepatic disease may stimulate the
renal synthesis of prostaglandins in some animals
and that when this augmented synthetic rate is in-
hibited by indomethacin, this may have a deleteri-
ous effect on renal function.
Human studies. Indomethacin, 150 mg/day for 3
days, reversibly reduced GFR in normal volunteers
who were sodium restricted (50 mEq/day for 4 days)
[73]. Although the GFR fell in 7 of 7 subjects (mean
decrease of 9 mI/mm) the effective renal plasma
flow was unchanged. In the same study, in 10 of 10
patients with renal parenchymal disease or a soli-
tary kidney, indomethacin reduced GFR and renal
plasma flow (16 mi/mm and 30 mllmin mean reduc-
tion) during sodium restriction. Other reports of the
effects of indomethacin in normal subjects have
shown no changes of GFR despite restriction of so-
dium to 9 mEq/day for 7 days and indomethacin,
150 mg/day [24, 74]. In 19 nephrotic patients, the
GFR decreased 35% (19 of 19 decreased) and renal
plasma flow fell 23% (16 of 19) [75]. Two patients
dropped their GFR by 65% and 76% during indo-
methacin therapy. These changes appeared within
24 hours and disappeared rapidly after cessation of
drug administration, suggesting a functional rather
than a structural alteration [75]. These patients re-
ceived a diet of 20 mEq of sodium per day, and it is
not known whether equally severe changes would
occur with higher sodium intakes. Interestingly, the
proteinuria diminished 55% during indomethacin
therapy. The reduced effective circulating plasma
volume, a consequence of hypoalbuminemia, un-
doubtedly predisposes nephrotic patients to reduc-
tions of GFR and RBF after inhibition of renal pros-
taglandin synthesis. Two recent reports reenforce
the importance of ineffective circulatory volume
and impaired cardiovascular function as pre-
disposing factors for renal toxicity of nonsteroidal
antiinflammatory drugs. Zipser et al administered
indomethacin or ibuprofen to 12 patients with se-
vere hepatic disease and ascites [24]. Urinary levels
of PGE2 were increased prior to indomethacin, in-
dicative of a compensatory role for renal prosta-
glandins in the maintenance of RBF in the presence
of renal vasoconstrictor factors. Creatinine clear-
ance decreased from 73 to 32 mllmin for the 12 pa-
tients, and serum creatinine rose from 0.7 to 1.2 mgI
dl after 200 mg of indomethacin (10 cases) or 2000
mg of ibuprofen (2 cases) over 24 hours. The pa-
tients with the more severe hyperreninism dropped
GFR from 68 to 18 mI/mm [24]. Indomethacin has
also been reported to cause decompensation of re-
nal function in a patient with severe congestive heart
failure [76]. Patients with ineffective circulating
plasma volume, high plasma renin and All, in-
creased alpha adrenergic neural activity, and renal
vasoconstriction depend on cortical synthesis of
prostaglandins to modulate the vasoconstriction.
Their response to indomethacin undoubtedly re-
sembles the response of animals infused with All or
subjected to hemorrhage or chronic bile duct-liga-
tion (that is, significant decrements of GFR and
RBF and increments of afferent and efferent arteri-
olar resistance). Figure 3 summarizes these inter-
actions.
The initial reports describing the effectiveness of
indomethacin to induce closure of a patent ductus
arteriosus in infants also noted the risk of transient
oliguric acute renal failure [77, 78]. These early
studies used higher doses of indomethacin (up to 5
mg/kg) than are used presently. At dosages of 0.2
mg/kg per 24 hours, 59 preterm infants responded
favorably, showing transient decreases of urine out-
put but no changes of serum creatinine [79]. There-
fore, it appears that inhibition of fatty acid cyclo-
oxygenase will close a patent ductus arteriosus in
almost all infants, and the risk of renal failure is
quite small.
Because the nonsteroidal antiinflammatory drugs
are used primarily in patients with arthritic dis-
eases, much attention has been paid to possible
deleterious actions of these compounds on the kid-
neys. There is no clear relation between aspirin
therapy and renal dysfunction in patients with rheu-
matoid arthritis. Epidemiologic studies of patients
with rheumatoid arthritis, treated with salicylates,
have not demonstrated an increased risk of renal
damage [80]. Nonetheless, there are definite neph-
rotoxic changes after salicylate therapy; it is not
known, however, whether this results from a direct
toxic action of salicylates or from the reduction of
prostaglandin synthesis. Salicylates can increase
renal epithelial cell excretion, increase excretion of
enzymes presumably derived from tubular cells,
and decrease renal concentrating and acidifying
Indomethacin inhib/
Stimulation of vasodilatory prostaglandins
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Fig. 3. Balance between vasoconstrictor and vasodilator factors in the kidney. Sodium depletion, hypotension, or an ineffective circula-
tory volume due to cirrhosis, nephrosis, or heart failure exert vasoconstrictor effects on the kidney that are modulated by release of
vasodilatory prostaglandins (PGE2 and PGI2). If prostaglandin synthesis is inhibited with an antiinflammatory drug, then renal vasocon-
striction is exaggerated, and GFR and RBF decrease significantly.
function [81]. After acute i.v. administration of ace-
tylsalicyclic acid to dogs, significant reductions of
RBF occurred when plasma salicylate concentra-
tions were 27.5 to 50.0 mg/dl, but no reductions of
GFR were observed [82]. Berg has reported signifi-
cant renal alterations after oral or i.v. administra-
tion of acetysalicyclic acid to normal subjects [83]
or to patients with chronic renal insufficiency [84].
In normal persons, aspirin transiently reduced so-
dium excretion, whereas in patients with reduced
GFR (23 7 mllmin) aspirin, 750 mg i.v., reduced
GFR, RBF, and sodium excretion by approximately
50% [84]. These changes disappeared after 6 to 10
hours.
Kimberly et al have published a series of papers
on their studies of the effects of aspirin and other
inhibitors of prostaglandin synthesis on renal func-
tion in patients with systemic lupus erythematosus
[85-87]. Approximately 50% of treated patients
with plasma salicylate concentrations of 27 1 mgI
dl showed increments of blood urea nitrogen and
serum creatinine after 7 or more days of aspirin
therapy [85]. The occurrence of aspirin-induced
renal dysfunction was strongly associated with pre-
existent glomerulonephritis and hypocomplemen-
temia secondary to systemic lupus erythematosus.
More detailed studies in 7 women with systemic
lupus erythematosus, treated with aspirin to
achieve serum salicylate levels of 25 to 30 mgldl for
1 week, confirmed the original report [86]. Creati-
nine clearance and inulin clearance decreased 18%
and 14%, respectively, and RBF (para-amino-
hippurate clearance) decreased 29%. Most of these
patients had previous evidence of lupus nephritis. It
is important to note that these patients had in-
creased excretory rates for PGE2 prior to aspirin
therapy and, in this regard, are similar to cirrhotic
patients in whom indomethacin caused severe re-
ductions of GFR. Other nonsteroidal inhibitors of
prostaglandin synthesis can induce similar decre-
ments of GFR in patients with systemic lupus ery-
thematosus [87].
Prostaglandin, renin release, and Bartter's syndrome
Prostaglandins and prostaglandin precursors are
potent stimuli of renin release. Arachidonic acid, in-
fused into the renal artery of experimental animals,
stimulates renin secretion [88—90]. This stimulation
of renin is dependent on the conversion of arachi-
donic acid to prostaglandin end products because
indomethacin blocks the response [88—90]. There is
substantial disagreement over the exact prostaglan-
din(s) responsible for stimulating renin secretion
[91]. Studies of PGI2 (prostacyclin), whether in-
fused into the renal artery or added to cortical
slices, have shown renin stimulation [92, 93]. PGE2
has enhanced renin release in vivo [93—95], but does
not directly stimulate renin release from cortical
slices [91]. PGF2a has generally exerted no effects
on renin secretion [94, 95]. The renin-stimulatory
actions of PGI2 and PGE2 are probably a direct ac-
tion on the juxtaglomerular cells, because the non-
filtering kidney, with no distal delivery of filtrate to
the macula densa, releases renin in response to
arachidonic acid or prostaglandins [95-97]. Indo-
methacin and other inhibitors of prostaglandin syn-
thesis inhibit but do not obliterate the response of
renin to stimuli. The experimental studies with in-
domethacin and other inhibitors of prostaglandin
synthesis have produced areas of agreement as well
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Fig. 4. Prostaglandins and renin release. This schema depicts our understanding of the literature on the subject of the renin-prostaglan-
din interaction. Other stimuli, besides those shown, do increase prostaglandin synthesis. The site at which baroreceptor and beta
adrenergic receptor stimulation trigger prostaglandin synthesis is conjectural. Because indomethacin inhibits the cyclo-oxygenase en-
zyme, renin secretion is reduced in response to most stimuli.
I
Renal kallikrein
1
as contradictory results and divergent interpreta-
tions. There is general agreement that indomethacin
blocks basal renin release in man and animals [98—
loll. Furthermore, most investigators agree that
the macula densa is of minor or minimal importance
in the prostaglandin-control of renin secretion [95—
97]. Virtually all studies also demonstrated signifi-
cant reduction or abolition by indomethacin of fu-
rosemide-stimulated renin secretion in animals and
man [97, 98, 100, 102—104]. Disagreement is focused
on the effects of indomethacin, and hence on the
role of prostaglandins, in baroreceptor and in beta
adrenergic receptor control of renin secretion by
renal juxtaglomerular cells. Several studies in dogs
showed no effect of indomethacin on renin release
after reduced renal perfusion pressure [31, 97],
whereas two other reports of experiments in dogs
documented indomethacin blockade of renin re-
lease after reduction of renal perfusion pressure
[96, 105]. Beta adrenergic stimulation of renin se-
cretion was reduced or blocked by indomethacin in
two studies (dog and rat [97, 106]), whereas indo-
methacin had little effect in other experiments (dog
and man on low sodium intake [100, 105, 107]). Al-
though a synthesis of these papers is risky, we believe
the following schema is reasonable. Prostaglandins
produced in the renal cortex, in glomeruli, and in ar-
terioles stimulate renin release. The order of stimula-
tory potency is PGI2 > PGE2> PGD2. Renin release
in basal and stimulated states are affected by these
prostaglandins. Prostaglandins may serve an intra-
cellular role related to cyclic AMP formation in the
juxtaglomerular and glomerular cells. Although re-
nm secretion is linked to these prostaglandins, this
is not an all or none response, and parallel or alter-
native pathways of activating renin secretion exist.
Therefore both baroreceptor and beta adrenergic
receptor stimulation can be blunted by indometha-
cm but can persist if adequately activated. One
must remember, when interpreting the indometha-
cm papers, that indomethacin has at least three ac-
tions on cyclic AMP systems (phosphodiesterase,
protein kinase, and cyclic AMP transport; see Table
4). Consequently, some of its actions on renin re-
lease, a cyclic AMP-controlled event, could be in-
dependent of prostaglandins. Figure 4 summarizes
the interrelations between renin, All, kinins, and
prostaglandin synthesis.
Recently, there has been renewed interest in
Bartter's syndrome because of the discovery of in-
creased renal excretion of PGE2 and beneficial re-
sults after treatment with inhibitors of pro staglandin
synthesis [74, 108—112].
Bartter's syndrome consists of many or all of the
following: hypokalemia, inappropriate renal losses
of potassium, sodium and chloride, metabolic alka-
losis, hyperreninemia associated with juxtaglo-
merular cellular hyperplasia, hyperaldosteronism,
reduced pressor responsiveness to All, elevated
urine and plasma levels of prostaglandins (PGE2
and PGI2), and normotension. The initiating defect
in these patients is unknown, but Gill and Bartter
have recently concluded that defective chloride
reabsorption in the ascending limb of Henle' s loop
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triggers distal tubular potassium losses, secondary
overproduction of prostaglandins, renin, and a!-
dosterone, and further losses of potassium and
chloride [113]. The evidence that potassium deple-
tion can induce secondary overproduction of pros-
taglandins by the kidney is contradictory. Although
potassium depletion in dogs apparently enhances
urinary excretion of PGE [114] studies in potas-
sium-depleted rats offer no supporting evidence that
renal synthesis of POE2 or PGFZc. is increased [115].
Treatment of these patients with indomethacin,
ibuprofen, naproxen, or aspirin has been beneficial.
These drugs differ only in their potency, and indo-
methacin appears most potent and has been the pre-
ferred drug [112]. These inhibitors of fatty acid cy-
clo-oxygenase have the following beneficial effects
in Bartter's syndrome: reductions of plasma and
urine prostaglandins as well as aldosterone and re-
nm, decreases of renal losses of potassium, sodium,
and chloride, improvement of metabolic alkalosis,
hypokalemia, and angiotensin resistance, and im-
proved sense of health and well-being [74, 108-112].
These patients also have abnormalities of the kalli-
krein-kinin system with increased urine kállikrein,
increased plasma bradykinin, and decreased kinins
[74, 110]. Indomethacin reduces urine kallikrein,
plasma kinins, and urine PGE2 in parallel, whereas
kinin excretion increases in patients with Bartter's
syndrome. Normal subjects under severe sodium
restriction (to raise aldosterone and urine kallikrein)
did not, however, change urine or plasma kinins af-
ter indomethacin despite a 40 to 50% decrement of
urine kallikrein [74]. It is unknown how prostaglan-
dins affect renal synthesis of kallikrein, although it
is presumed that overproduction of prostaglandins,
in the kidney and systemically, stimulates urine kal-
likrein and plasma kinin because indomethacin sup-
presses these parameters. A direct action of indo-
methacin on the kallikrein-kinin system has not
been ruled out. It is noteworthy that most cases of
Bartter's syndrome respond to indomethacin with a
decrease of creatinine clearance of 15 to 30%,
which is transient and improves over 3 to 5 days
[74] or is persistent at least for 1 week [112].
Renal prostaglandins, renin, aldosterone, and po-
tassium may also be interrelated in the syndrome of
hyporeninemic hypoaldosteronism [116]. Urine
POE2 and PGFZ. were reported to be decreased in
two cases of hyporeninemic hypoaldosteronism
[116, 117]. Indomethacin induced this syndrome in
a patient with mild chronic renal insufficiency [117],
and the hyperkalemia improved after stopping indo-
methacin. Vinci et al observed no increases of
serum potassium in indomethacin-treated normal
subjects despite a small decrease of renal potassium
excretion [74]. Hyperkalemia alter indomethacin is
probably rare and restricted to cases with hyporeni-
nemic hyposidosteronism.
Prostaglandin inhibition: Sodium and water cx-
cretiofl. We will not attempt to review the complex
and contradictory literature concerning the re-
sponse of renal prostaglandins to the alteration of
sodium intake or the interrelation between natriur-
esis and renal secretion or excretion of prostaglan-
dins. Many reports have been published on the ef-
fects of aspirin, indomethacin, and related drugs on
sodium and water balance in man and animals [5,
118]. There is no unanimity among these papers.
Antiinflammatory drugs can alter sodium excretion
through a direct action by removal of the effects of
prostaglandins on tubular sodium reabsorption
[119—121], reduction of RBF with secondary effects
on sodium excretion, or competition for mineral-
ocorticoid receptors [122]. The direct removal of a
prostaglandin action on sodium transport seems the
most plausible explanation for the majority of stud-
ies showing a decrement of sodium excretion after
indomethacin. Acute administration of aspirin, in-
domethacin, or meclofenamate reduced renal ex-
cretion of sodium and water in dogs [82, 123], rats
[122, 124], and man [24, 73, 75, 84, 125] either in the
basal state or in some experiments only after so-
dium loading or sodium depletion. Other experi-
ments with indomethacin have not shown altera-
tions of sodium excretion [74, 99, 126]. We found no
effects of indomethacin or meclofenamate on so-
dium excretion in the conscious dog [9]. Oliw et al
found that indomethacin potentiated the natriuretic
response to sodium loading in rabbits [127]. Many
of these responses are acute and transient, and it ap-
pears that the chronic effects of these drugs are less
dramatic [74, 99]. Although inhibition of renal pros-
taglandin synthesis augments, acutely, the renal re-
sponse to vasopressin [128, 129], there is no clinical
or experimental evidence of chronic retention of
water or dilutional hyponatremia.
Because furosemide, given i.v., stimulated renal
excretion (that is, synthesis) of PGE2 and PGF2a in
animals and man [130-133], many investigators
have evaluated the interactions of furosemide and
other diuretics with indomethacin. Indomethacin
reduced the acute natriuretic response to furose-
mide in the dog, rabbit, and man [99, 134-137]. Sim-
ilar results were seen with MK447 and indometha-
cm in rats [138] and bumetanide and indomethacin
in dogs [139]. Other authors report no significant
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negative interaction between diuretics and indo-
methacin [100, 126].
It seems reasonable to conclude that prostaglan-
din inhibitory drugs can acutely reduce renal excre-
tion of sodium and water and attenuate the renal
response to diuretics. It is also likely that this action
is entirely dissipated after several days unless the
patient has a disease characterized by severe so-
dium retention (cirrhosis, heart failure, nephrotic
syndrome). The recent reports of antagonism of
the chronic antihypertensive actions of beta adren-
ergic blockers and diuretics by indomethacin are
undoubtedly multifactoral and not simply secondary
to a reduction of sodium excretion [140, 1411.
Summary. The kidney synthesizes all known
prostaglandins and thromboxanes, namely, PGE2,
PGI2, PGF2,, PGD2, and TxA2. The major physio-
logic functions of these products of arachidonate
oxygenation are control of RBF and GFR, stimula-
tion of renin secretion, and modulation of sodium
and water excretion. Indomethacin, aspirin, and re-
lated drugs inhibit fatty acid cyclo-oxygenase and
thereby inhibit prostaglandin synthesis. Indometha-
cm in conventional doses, reduces renal synthesis
of prostaglandins by greater than 75% within 1 hour
of parenteral administration. These inhibitory drugs
exert few, if any, deleterious effects on renal func-
tion in normal man or conscious, normal animals. If
animals are volume-depleted, vasoconstricted, or
bile-duct-ligated, then indomethacin can significant-
ly decrease RBF, GFR, and sodium and water ex-
cretion. Patients with severe liver disease and as-
cites, lupus erythematosus, primary glomerular dis-
ease with and without the nephrotic syndrome, and
advanced congestive heart failure will often re-
spond to prostaglandin-synthesis-inhibitors with re-
ductions of GFR and decrements of salt excretion.
Suppression of renal prostaglandin synthesis in pa-
tients with Bartter's syndrome exerts salutary
changes in the clinical course.
Reprint requests to Dr. M. J. Dunn, Department of Medicine,
Division of Nephrology, Case Western Reserve University, Uni-
versity Hospitals, Cleveland, Ohio 44/06, USA
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